September 7, 2017 / 11:23 AM / 10 months ago

Bristol-Myers kidney cancer drug meets main goal of late-stage trial

Sept 7 (Reuters) - Bristol-Myers Squibb Co said on Thursday its combination drug to treat a type of kidney cancer met one of the main goals of overall survival in a late-stage study.

The trial was testing a combination of Opdivo and Yervoy, Bristol-Myers’ top drugs, in previously untreated patients with advanced or metastatic renal cell carcinoma.

The results were compared with a standard-of-care drug sunitinib.

Last month, the company said the combination treatment had failed to improve progression-free survival in patients in the same late-stage trial, but had met one of the other main goals. (Reporting by Divya Grover in Bengaluru; Editing by Savio D’Souza)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below